Phase II Study of Nivolumab in Combination with Ipilimumab in Patients with Advanced Neuroendocrine Tumors
Summary
The purpose of this phase II study is to evaluate the safety and efficacy of nivolumab plus ipilimumab in patients with advanced neuroendocrine tumors, including pancreatic neuroendocrine tumors (pNETs).
General Information
NCT#: NCT03420521
Study ID: J17156
Trial Phase: Phase II
Trial Sponsor: Sidney Kimmel Comprehensive Cancer Center
Therapies Used in This Trial: Ipilimumab, Nivolumab